[go: up one dir, main page]

NO20043022L - 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister - Google Patents

5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister

Info

Publication number
NO20043022L
NO20043022L NO20043022A NO20043022A NO20043022L NO 20043022 L NO20043022 L NO 20043022L NO 20043022 A NO20043022 A NO 20043022A NO 20043022 A NO20043022 A NO 20043022A NO 20043022 L NO20043022 L NO 20043022L
Authority
NO
Norway
Prior art keywords
diaryl
pyrazine
antagonists
amide derivatives
amide
Prior art date
Application number
NO20043022A
Other languages
English (en)
Norwegian (no)
Inventor
Stig Jonas Bostrom
Anna Ingrid Kristina Berggren
Stig Thomas Elebring
Peter Greasley
Emma Terricabra
Johan Michael Wilstermann
Original Assignee
Astrazeneca Ab Global Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab Global Ip filed Critical Astrazeneca Ab Global Ip
Publication of NO20043022L publication Critical patent/NO20043022L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20043022A 2001-12-19 2004-07-15 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister NO20043022L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0104330A SE0104330D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents
PCT/GB2002/005742 WO2003051851A1 (fr) 2001-12-19 2002-12-18 Derives de 5, 6-diaryl-pyrazine-2-amide comme antagonistes de cb1

Publications (1)

Publication Number Publication Date
NO20043022L true NO20043022L (no) 2004-07-15

Family

ID=20286429

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043022A NO20043022L (no) 2001-12-19 2004-07-15 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister

Country Status (25)

Country Link
US (1) US7342019B2 (fr)
EP (1) EP1458690B1 (fr)
JP (1) JP2005517655A (fr)
KR (1) KR20040068286A (fr)
CN (1) CN1620438A (fr)
AR (1) AR038044A1 (fr)
AT (1) ATE354570T1 (fr)
AU (1) AU2002352425A1 (fr)
BR (1) BR0214989A (fr)
CA (1) CA2469786A1 (fr)
CO (1) CO5590917A2 (fr)
DE (1) DE60218340T2 (fr)
ES (1) ES2280599T3 (fr)
HU (1) HUP0402026A3 (fr)
IL (1) IL162377A0 (fr)
IS (1) IS7314A (fr)
MX (1) MXPA04005990A (fr)
NO (1) NO20043022L (fr)
NZ (1) NZ533275A (fr)
PL (1) PL369731A1 (fr)
RU (1) RU2004116916A (fr)
SE (1) SE0104330D0 (fr)
TW (1) TW200410694A (fr)
WO (1) WO2003051851A1 (fr)
ZA (1) ZA200404805B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
WO2004029204A2 (fr) 2002-09-27 2004-04-08 Merck & Co., Inc. Pyrimidines substituees
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314049D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2004111033A1 (fr) * 2003-06-18 2004-12-23 Astrazeneca Ab Agents therapeutiques
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
EP1644335A4 (fr) 2003-07-11 2008-06-04 Bristol Myers Squibb Co Derives de tetrahydroquinoleine constituant des modulateurs des recepteurs des cannabinoides
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
CA2537535A1 (fr) * 2003-09-02 2005-03-10 Solvay Pharmaceuticals Gmbh Nouvelles utilisations medicales d'antagonistes selectifs du recepteur cb<sb>1</sb>
US7320805B2 (en) * 2003-10-01 2008-01-22 Institut National De La Sante Et De La Recherche Medicale CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver
EP1670460B1 (fr) 2003-10-10 2014-11-26 Bristol-Myers Squibb Company Derives de pyrazole utilises comme modulateurs du recepteur de cannabinoide
TW200528102A (en) * 2003-10-24 2005-09-01 Solvay Pharm Gmbh Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
RU2006117637A (ru) * 2003-10-24 2007-12-10 Зольвай Фармасьютиклз Гмбх (De) Комбинированное лечение ожирения с применением избирательных антагонистов cb1-рецептора и ингибиторов липаз
GB0327331D0 (en) * 2003-11-25 2003-12-31 Astrazeneca Ab Therapeutic agents
EP1734963A4 (fr) 2004-04-02 2008-06-18 Merck & Co Inc Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
AU2005298692A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions
RU2404164C2 (ru) 2005-04-06 2010-11-20 Ф.Хоффманн-Ля Рош Аг Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
JP2008536950A (ja) * 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
JP2008545009A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
BRPI0717845A2 (pt) * 2006-10-04 2015-06-16 Hoffmann La Roche Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
PE20081659A1 (es) 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
CL2008000017A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
ATE523507T1 (de) 2007-01-04 2011-09-15 Prosidion Ltd Piperidin-gpcr-agonisten
EA016507B1 (ru) 2007-01-04 2012-05-30 Прозидион Лимитед Пиперидиновые агонисты gpcr
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
WO2010079241A1 (fr) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
US9403808B2 (en) * 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives
WO2022031946A1 (fr) 2020-08-06 2022-02-10 Chdi Foundation, Inc. Composés hétérobiaryles et agents d'imagerie pour l'imagerie de la protéine huntingtine
AR131658A1 (es) * 2023-01-30 2025-04-16 Eurofarma Laboratorios S A Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y sus kits
AR131690A1 (es) * 2023-01-30 2025-04-23 Eurofarma Laboratorios S A COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH458361A (de) * 1965-01-15 1968-06-30 Eprova Ag Verfahren zur Herstellung von Pyrazincarbonsäuren
JPS5322529A (en) * 1976-08-13 1978-03-02 Nippon Soda Co Ltd Dihydropyrazine derivative and its preparation
EP0397859A4 (en) * 1987-11-12 1990-12-19 Terumo Kabushiki Kaisha Pyrazine derivatives and medicinal preparation containing same
JPH06501926A (ja) * 1990-08-06 1994-03-03 藤沢薬品工業株式会社 複素環式化合物
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.

Also Published As

Publication number Publication date
US20050032808A1 (en) 2005-02-10
HUP0402026A3 (en) 2005-08-29
BR0214989A (pt) 2004-12-14
AU2002352425A1 (en) 2003-06-30
AR038044A1 (es) 2004-12-22
EP1458690A1 (fr) 2004-09-22
PL369731A1 (en) 2005-05-02
JP2005517655A (ja) 2005-06-16
NZ533275A (en) 2006-02-24
KR20040068286A (ko) 2004-07-30
MXPA04005990A (es) 2004-09-27
RU2004116916A (ru) 2005-11-10
IS7314A (is) 2004-06-16
ES2280599T3 (es) 2007-09-16
CN1620438A (zh) 2005-05-25
WO2003051851A1 (fr) 2003-06-26
HUP0402026A2 (hu) 2005-02-28
DE60218340T2 (de) 2007-11-29
CO5590917A2 (es) 2005-12-30
TW200410694A (en) 2004-07-01
US7342019B2 (en) 2008-03-11
DE60218340D1 (de) 2007-04-05
ATE354570T1 (de) 2007-03-15
EP1458690B1 (fr) 2007-02-21
CA2469786A1 (fr) 2003-06-26
SE0104330D0 (sv) 2001-12-19
ZA200404805B (en) 2005-08-15
IL162377A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
NO20043022L (no) 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister
DE60216115D1 (de) BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE
DK1429761T3 (da) Hidtil ukendte 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning
NO20032892D0 (no) 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning
DE60214428D1 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
CY2014041I1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
DE50210707D1 (de) Substituierte 2-pyridin-cyclohexan-1,4-diaminderivate
DK1379522T3 (da) Dihydro-benzo(b)(1,4)diazeping-2-on-derivater som MGLUR2-antagonister I
DE60225563D1 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
NO20041560L (no) 1,6-nafthyridinderivater som antidiabetiske midler
ATE299868T1 (de) Dihydro-benzo (b) (1,4) diazepin-2-on-derivate als mglur2 antagonisten
DK1414803T3 (da) Pyrazolylcarboxanilider som fungicider
NO20023485L (no) 1,3-disubstituerte pyrrolidiner som alfa-2- adrenoceptorantagonister
NO20041075L (no) Ny 1, 2, 4-triazolforbindelse
MXPA03006991A (es) Derivados de piperidina como antagonistas de neurocinina 1.
EP1426370A4 (fr) Derive de propanolamine a noyau 1,4-benzodioxane
ATE326467T1 (de) Imidazo 1,2-aöpyridine
DE50107988D1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
NO20021251D0 (no) Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister
DE60224221D1 (de) Aminotetralinderivate, antagonisten von muscarinrezeptoren
NO20042980L (no) 3,4-dihydro-1H-isokinolin-2-yl-derivater
NO20044405L (no) Neurotensinaktive 2,3-diaryl-pyrazolidin derivater
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður
DE50214487D1 (de) Substituierte 1,5-diaminopentan-3-ol-verbindungen
IS7299A (is) 3,4-díhýdró-1H-ísókínólóín-2-ýl-afleiður

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application